NOTCH1 Reactivates STING to Reverse Immune Suppression in SCLC – NCI Center for Cancer Research
NCI Center for Cancer Research shared a post on LinkedIn about a paper by Yoo Sun Kim et al. published in the Journal of Clinical Investigation:
“NIH researchers in the Center for Cancer Research discovered that the activation of NOTCH1, a gene known to control cell differentiation and growth, stimulates a robust immune response in small cell lung cancer. Expression of this gene can also predict survival with immunotherapy.
Read more about their findings.”
Title: NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
Authors: Yoo Sun Kim, Barzin Y Nabet, Briana N Cortez, Nai-Yun Sun, Robin Sebastian, Christophe E Redon, Anagh Ray, Liang Liu, Afeez A Ishola, Sarah Loew, Anjali Dhall, Sivasish Sindiri, Velimir Gayevskiy, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Noemi Kedei, Thorkell Andresson, Sudipto Das, Suresh Kumar, Alan E Bers, Hongliang Zhang, Alberto Chiappori, Priyanka Gopal, Mohamed E Abazeed, Haobin Chen, Mirit I Aladjem, Yves Pommier, Moises J Velez, David S Shames, Nitin Roper
You can read the Full Article on the Journal of Clinical Investigation.
More posts featuring NCI Center for Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023